4,955.00
-10.00
(-0.20%)
May 17 - Close
TYO
data delayed by 20 mins -
Disclaimer
Currency in JPY
| Range | 4,930.00 - 4,975.00 |
| 52 week | 3,225.00 - 5,520.00 |
| Open | 4,950.00 |
| Vol / Avg. | 2.84M/706.00 |
| Mkt cap | 3.91T |
| P/E | 29.81 |
| Div/yield | 90.00/3.63 |
| EPS | 166.23 |
| Shares | 789.46M |
| Beta | - |
| Inst. own | - |
Events
Jul 29, 2013
Q1 2014 Takeda Pharmaceutical Co Ltd Earnings Release
Jun 26, 2013
Takeda Pharmaceutical Co Ltd Annual Shareholder Meeting (Japanese)
May 9, 2013
Full Year 2013 Takeda Pharmaceutical Co Ltd Earnings and Mid-Range Growth Strategy Conference Call
May 9, 2013
Full Year 2013 Takeda Pharmaceutical Co Ltd Earnings and Mid-Range Growth Strategy Presentation (Japanese)
May 9, 2013
Full Year 2013 Takeda Pharmaceutical Co Ltd Earnings and Mid-Range Growth Strategy Presentation
Mar 19, 2013
NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84- Conference Call
Mar 11, 2013
Takeda Pharmaceutical Co Ltd at EBD BIO-Europe Spring
Feb 25, 2013
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS� (peginesatide) Injection - Conference Call
|
|
Key stats and ratios
| Q1 (Mar '13) | 2013 | |
| Net profit margin | -1.86% | 8.58% |
| Operating margin | -18.02% | 5.26% |
| EBITD margin | - | 20.78% |
| Return on average assets | -0.71% | 3.55% |
| Return on average equity | -1.46% | 6.29% |
| Employees | 30,305 | - |
| Carbon Disclosure Rating | - | 70/100 |
Address
Takeda Midosuji Bldg. 4-1-1, Dosho-machi, Chuo-ku
OSAKA-SHI, OSK 540-8645
Japan
+81-6-62042111 (Phone)
+81-6-62042880 (Fax)
OSAKA-SHI, OSK 540-8645
Japan
+81-6-62042111 (Phone)
+81-6-62042880 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. On September 30, 2011, the Company acquired 100% interests in Nycomed A/S. In January 2012, the Company acquired an America-based company.
Officers and directors
| Yasuchika Hasegawa | President, Representative Director | |
| Deborah L. Dunsire M.D. | President of Subsidiary, Director | |
| Frank M.D. Morich | Chief Commercial Officer, President of Subsidiary, Director | |
| Tadataka Yamada M.D. | Chief Medical and Scientific Officer, Director | |
| Yasuhiko Yamanaka | Managing Director | |
| Toyoji Yoshida | Managing Director, President of Subsidiary | |
| Masato Iwasaki | Chief Director of Pharmaceutical Sales, Director | |
| Yorihiko Kojima | Independent Director | |
| Fumio Sudo | Independent Director |